Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac for the Northern Hemisphere Season 2013/2014. An Open-Label, Baseline- Controlled Study in Two Age Groups: Adult Subjects ≥ 18 and ≤ 60 Years and Elderly Subjects ≥ 61 Years of Age.
Latest Information Update: 25 Aug 2014
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Biologicals BV
- 30 Jul 2013 New trial record